ORIGINAL RESEARCH article
Front. Immunol.
Sec. Cancer Immunity and Immunotherapy
Volume 16 - 2025 | doi: 10.3389/fimmu.2025.1598484
This article is part of the Research TopicThe Insights of Multi-Omics into the Microenvironment After Tumor Metastasis: A Paradigm Shift in Molecular Targeting Modeling and Immunotherapy for Advanced Cancer PatientsView all 5 articles
Splenic Volume as a Predictor of Survival in Cancer Patients Treated with Immune Checkpoint Inhibitors
Provisionally accepted
- Renmin Hospital of Wuhan University, Wuhan, China
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
Objective: This investigation seeks to examine the association between spleen volume and prognosis in cancer patients undergoing immune checkpoint inhibitor (ICI) treatment.Methods: We performed a retrospective analysis involving 61 patients diagnosed with hepatocellular carcinoma (HCC) who received ICIs at our institution. We evaluated the relationship between baseline splenic volume and its changes during ICI therapy concerning overall survival (OS) and progression-free survival (PFS) using a log-rank test. To identify relevant literature, we searched databases such as PubMed, EMBASE, the Cochrane Library, and Google Scholar up until February 20, 2024. The primary metrics assessed were hazard ratios (HR) for both OS and PFS, with pooled estimates and corresponding 95% confidence intervals (CIs) calculated.Results: Within our study population, findings demonstrated a significantly decreased OS (HR: 2.02, 95% CI: 1.08-3.77, p = 0.027) and PFS (HR: 1.84, 95% CI: 1.05-3.21, p = 0.032) in HCC patients with a high baseline spleen volume, compared to individuals with lower spleen volumes. Additionally, HCC patients who experienced an increase in spleen volume during ICI therapy exhibited significantly poorer OS (HR: 2.27, 95% CI:1.17-4.41, p = 0.016) and PFS (HR: 2.40, 95% CI: 1.30-4.41, p = 0.005) than those whose spleen volume decreased. The meta-analysis results revealed that subjects with higher spleen volumes had a significantly reduced OS (HR: 1.74, 95% CI: 1.12-2.72, p = 0.014) and PFS (HR: 1.35, 95% CI: 1.15-1.58, p < 0.001) compared to counterparts with lower volumes. Furthermore, the data clearly highlighted that patients with increases in splenic volume faced significantly poorer clinical outcomes, as indicated by reduced OS (HR: 1.83, 95% CI: 1.36-2.46, p < 0.001) and PFS (HR: 1.70, 95% CI: 1.28-2.25, p < 0.001) relative to those with decreases in splenic size.Conclusion: A higher baseline spleen volume and an increase in spleen volume during ICI therapy were predictors of a poor prognosis in cancer patients treated with ICI.
Keywords: immune checkpoint inhibitors, Cancer, Splenic volume, prognosis, Hepatocellular Carcinoma
Received: 23 Mar 2025; Accepted: 12 May 2025.
Copyright: © 2025 Zhang, Fu, Zhang, Zhou and Wang. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Lilong Zhang, Renmin Hospital of Wuhan University, Wuhan, China
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.